Free Flow Medical, Inc.

What Free Flow Medical, Inc. does

Free Flow Medical, Inc. is a private medical device company founded in December 2017 and headquartered in Fremont, California, that develops bronchoscopic lung volume reduction (BLVR) implants for the treatment of severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's core technology is the FreeFlow Coil System, a Nitinol wire implant with shape memory that is delivered bronchoscopically into subsegmental airways and mechanically compresses diseased lung tissue to decompress healthier regions. The portfolio includes the FreeFlow Coil #2 System (first generation with improved delivery, launched in Europe January 2023), the FreeFlow Coil #4 System (next-generation with dual anchoring, introduced as a pilot in January 2022), and the Compass QCT Report platform for quantitative CT-based patient selection (launched in Europe February 2022). A third technology platform, the LungFlow Catheter System for chronic bronchitis, had its first patient treated in April 2025.

The company operates a direct enterprise field sales model targeting hospitals and lung centers with pulmonology and thoracic surgery departments. Commercial activity is concentrated in Europe, where the company holds CE marking (received November 2020) and has established reimbursement in Germany (since December 2018). The company has treated patients in Germany, Switzerland, France, Austria, and the Netherlands, and reports a presence in seven or more European countries. The FreeFlow Coil System is not approved for sale in the United States, though a first US patient was treated in November 2022. The company monetizes exclusively through hardware sales of implantable devices and is privately held by co-founders Mark Mathis (CEO), Kim Mathis (CFO), and Mike Lau (Director of Operations), with no publicly disclosed venture capital or private equity funding rounds despite a reported $4.92 million raised across two small rounds in 2019 and 2020.

Name

Free Flow Medical, Inc.

Legal name

Free Flow Medical, Inc.

Website

https://freeflowmedical.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Free Flow Medical is a private medtech company that develops bronchoscopic lung volume reduction devices using Nitinol coil implants to treat severe emphysema patients, selling directly to hospitals across European markets.

Ownership category

akta.pro rank

Product category

Interventional Pulmonology Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Bronchoscopy & Interventional Pulmonology (HLAKANAJ)

akta.pro secondary industry

Anesthesia & Airway Management Equipment (Workstations, Laryngoscopy, Ventilation adjuncts) (HLAHADAJ)

Keywords

• Bronchoscopic lung volume reduction
• Medical devices
• Emphysema treatment
• Interventional pulmonology
• Nitinol coil implants

Headquarters

HQ city

Fremont

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

1. Medical Device Sales: Sale of implantable medical devices (Coil systems) to hospitals and healthcare facilities for bronchoscopic lung volume reduction procedures in severe emphysema patients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Free Flow Medical develops and commercializes bronchoscopic lung volume reduction (BLVR) implantable devices made from shape-memory Nitinol wire for the minimally invasive treatment of severe emphysema. The company's portfolio includes the FreeFlow Coil #2 System and the next-generation FreeFlow Coil #4 System, alongside the LungFlow Catheter System for chronic bronchitis, sold directly to hospitals and pulmonology/thoracic surgery departments across Europe.

Product overview

Free Flow Medical develops medical devices for pulmonary medicine, specifically targeting COPD and emphysema patients. Their product portfolio includes the FreeFlow® Coil Systems (#2 and #4) for bronchoscopic lung volume reduction (BLVR) in severe emphysema patients, and the LungFlow Catheter System for chronic bronchitis treatment. The Coil Systems are nitinol wire implants delivered via bronchoscopy that compress diseased lung tissue to improve function of healthier areas.

Differentiator

Problem solved

Functional benefit

Brands

• FreeFlow® Coil System: Bronchoscopic lung volume reduction (BLVR) treatment indicated for severe emphysema patients. Includes Coil #2 System (original with improved delivery technology) and Coil #4 System (next generation, pilot phase).
• LungFlow Catheter System
• Compass® QCT Report

Products and services

• FreeFlow® Coil #2 System
• FreeFlow® Coil #4 System
• LungFlow Catheter System

Quantifiable outcome

• SGRQ score improvement of -8.6 to -15 points (P<0.001)
• +4 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators3 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Spiration (Olympus): Spiration's Valve System, distributed by Olympus, is another FDA-approved endobronchial valve for treating severe emphysema. It competes with FreeFlow in the same hospital pulmonology/thoracic surgery accounts using a different but overlapping mechanism.
• PneumRx (acquired by BTG, now Boston Scientific): PneumRx developed the RePneu Coil, the historical direct precursor to FreeFlow's Nitinol coil system for BLVR. It was acquired by BTG in 2015 and is now part of Boston Scientific — the same acquirer of the founder's prior company (Genesis Medical). The Coil #2 and #4 compete head-to-head with the legacy RePneu design.
• Pulmonx Corporation: Pulmonx markets the Zephyr Endobronchial Valve, the leading FDA-approved BLVR device for severe emphysema. It is the most direct competitor to FreeFlow Coils in the lung volume reduction category, addressing the same patient population with a different mechanism (one-way valves vs. Nitinol coils).

Broad incumbents

• Boston Scientific Corporation: Boston Scientific acquired PneumRx (coil-based BLVR) and is a broad incumbent in interventional pulmonology. It has the salesforce, regulatory infrastructure, and hospital relationships to dominate BLVR and could acquire FreeFlow as a complementary asset.
• Olympus Corporation: Olympus is the dominant manufacturer of bronchoscopes and other endoscopy equipment used in every BLVR procedure. While not a therapeutic device competitor, it controls the diagnostic and delivery infrastructure that FreeFlow's coil procedures depend on.
• Medtronic plc: Medtronic is a large diversified medtech incumbent with significant presence in respiratory and thoracic surgery. While it does not currently market a direct BLVR device, it has the resources to enter or acquire into the category and compete with FreeFlow's hospital accounts.

Emerging players

• CSA Medical: CSA Medical markets the RejuvenAir Metered Cryospray System for chronic bronchitis, a bronchoscopic liquid nitrogen spray cryotherapy device. It directly overlaps with FreeFlow's LungFlow Catheter platform as a device-based treatment for chronic bronchitis.
• Nuvaira: Nuvaira is developing targeted lung denervation (TLD) for COPD, a catheter-based bronchoscopic intervention. While not a direct BLVR device, it targets the same patient population and pulmonology call point with a different therapeutic mechanism, making it a relevant emerging competitor.

Others

• Penumbra, Inc. Penumbra is a thrombectomy and broader interventional device company. While not directly in BLVR, it has expanded into adjacent interventional and lung therapy categories and could represent a comparable mid-cap interventional medtech trajectory or acquirer profile.
• Intuitive Surgical: Intuitive Surgical's Ion robotic bronchoscopy platform is increasingly used for advanced bronchoscopic interventions including potential BLVR adjunct procedures. It is an enabling technology and potential partner in the interventional pulmonology space where FreeFlow operates.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/freeflowmedical

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Free Flow Medical, Inc.